Graham Fagg joined Rosetta in 2003. Graham has more than 35 years of experience in the pharma/biotech sectors, encompassing R&D, business development, strategic planning, and corporate and venture investing. He held senior positions at Ciba/Novartis and the Wellcome Trust, an investment role at Accel Partners, and was a partner at Seroba Life Sciences, where he was on the Boards of Ario Pharma, Quanta Fluid Solutions and Xention. Graham holds a PhD from University College London.